tesamorelin-peptides-for-sale The CBD3 peptide is a promising therapeutic agent derived from the collapsin response mediator protein 2 (CRMP-2). This peptide has garnered significant attention for its potential to target voltage-gated calcium channels, particularly Cav2.2, and its efficacy in alleviating neuropathic painTAT-CBD3 | CRMP2-NMDAR抑制剂. Research indicates that the CBD3 peptide can disrupt the interaction between CRMP-2 and Cav2.2 channels, thereby reducing calcium influx, transmitter release, and subsequent pain signaling. This mechanism of action suggests a novel approach to pain management, potentially offering an alternative to existing analgesics like gabapentin.
The core of therapeutic interest lies in the CBD3 peptide itself, a 15-amino acid sequence identified as the calcium-binding domain 3 of CRMP-2. Its ability to interfere with calcium channel function is central to its analgesic properties. However, to enhance its delivery and efficacy, various modified versions have been developed2023年11月13日—The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it,outperformed gabapentinwithout troublesome side effects..
One notable derivative is TAT-CBD3, which incorporates the TAT cell-penetrating motif from the HIV-1 protein. This fusion allows the peptide to more effectively cross cell membranes and reach its intracellular targets, leading to sustained relief of neuropathic pain in animal models. Other modifications, such as N-terminal myristoylation (Myr-tat-CBD3), aim to improve membrane tethering and localization near the calcium channels, further enhancing its therapeutic potential.Sustained relief of neuropathic pain by AAV-targeted ...
The primary application explored for the CBD3 peptide and its derivatives is the treatment of neuropathic painFurther insights into the antinociceptive potential of a .... This type of pain, often characterized by burning, tingling, or shooting sensations, arises from damage to the nervous system and can be notoriously difficult to manage. Studies have shown that TAT-CBD3 and related peptides can effectively ameliorate hypersensitivity associated with chronic inflammatory and neuropathic pain states in rodents.
The mechanism involves the peptide's direct interaction with the CRMP-2 protein. By uncoupling CRMP-2 from Cav2.2 channels, the CBD3 peptide prevents the surface trafficking of these channels and reduces the inward flow of calcium ions. This modulation of Ca(2+) channel-binding domain 3 function is crucial for reducing neuronal excitability and pain transmission. Furthermore, research suggests that CBD3 can also impact NMDAR-mediated calcium influx, contributing to its neuroprotective and analgesic effects.Aβ 25-35 -induced autophagy and apoptosis are prevented by ...
While neuropathic pain relief is a major focus, the CBD3 peptide also exhibits neuroprotective properties.作者：Y Ji·2019·被引用次数：22—A short peptide from CRMP2, designated theCa2+channel-binding domain 3 (CBD3) peptide, has recently emerged as a Ca2+channel blocker that ... Studies have demonstrated its ability to protect cells from excitotoxicity and traumatic brain injury.2011年6月6日—Thepeptide,CBD3, has been shown in mice to interfere with signals that navigate calcium channels to produce pain. For instance, certain peptides derived from CRMP-2, like ST2-104 (a nona-arginine-fused CBD3 peptide), have shown promise in protecting neuronal cells from damage induced by glutamateSustained relief of neuropathic pain by AAV-targeted .... This neuroprotective potential might stem from its ability to limit excessive calcium entry and modulate apoptotic pathways.
The development of CBD3063, a selective, first-in-class, CRMP2-based peptidomimetic small molecule, further highlights the therapeutic promise of targeting the CRMP-2 pathway. This small molecule acts as an allosteric regulator of Cav2.CRMP-2 peptide mediated decrease of high and low voltage ...2, achieving analgesia and pain relief, suggesting that non-peptide mimetics of CBD3 could also be viable therapeutic agents.Myr-tat-CBD3 | Myr-YGRKKRRQRRRARSRLAELRGVPRGL
The ongoing research into the CBD3 peptide and its analogs, including variations like TAT-CBD3A6K, underscores a strong pipeline for novel pain therapeutics. Systemic injections of these peptides have shown efficacy in animal models, paving the way for potential clinical translation. However, challenges remain, such as optimizing delivery methods, ensuring long-term efficacy, and thoroughly evaluating safety profiles.作者：S Perez-Miller·2024·被引用次数：10—CBD3 uncouples CRMP2–CaV2.2 bindingto decrease CaV2.2 surface localization and calcium currents. These changes occur at presynaptic sites of nociceptive ... The development of methods for sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide indicates a move towards more advanced delivery systems.作者：Y Yao·2021·被引用次数：12—... (CBD3) peptide, that conferred protection against excitotoxicity and traumatic brain injury. ST2-104, a nona-arginine (R9)-fused CBD3 peptide, exerted ... As research progresses, the CBD3 peptide and its related compounds represent a significant advancement in understanding and treating chronic pain and neurological conditions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.